FindTrial
Sign In

The impact of radiation therapy on outcome for myasthenia gravis patients with thymoma

The impact of radiation therapy on outcome for myasthenia gravis patients with thymoma

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100044733
Enrollment
Unknown
Registered
2021-03-26
Start date
2021-03-30
Completion date
Unknown
Last updated
2021-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

myasthenia gravis

Interventions

grouped according to different subtypes of myasthenia gravis and different radiotherapy modes:radiation therapy

Sponsors

Shanghai Chest Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Pathologically diagnosed thymoma; 2. Clinically diagnosed myasthenia gravis (anti-AChR +, Electromyography +); 3. Indication of radiotherapy for thymoma (neo-adjuvant, adjuvant, definitive, palliative); 4. Aged >= 18 years; 5. Mild MG symptoms (MGFA type I/II; asymptomatic or MME after treatment).

Exclusion criteria

Exclusion criteria: 1. Massive pleural effusion; 2. Active pulmonary inflammation or interstitial pneumonia; 3. In plan of or in pregnancy.

Design outcomes

Primary

MeasureTime frame
alteration of myasthenia gravis symptom;—

Secondary

MeasureTime frame
risk factors of MG exacerbation;—

Countries

China

Contacts

Public ContactWang Changlu

Shanghai Chest Hospital

2452183417@qq.com+86 13817125147

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026